Back to List View Graph View

DNMT1

DNA methyltransferase 1 (DNMT1) is a DNA methyltransferase and a central target in studies of DNA methylation–associated disease mechanisms.

Where the papers sit

9 papers from the last 6 months study DNMT1 directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 3 human data · 6 preclinical

Themes 3 themes

  • DNMT1 Disease Mechanisms

    DNMT1 recurs as a methylation regulator linking distinct diseases to altered signaling, metabolism and treatment response. Named mechanisms include QDPR silencing in lung adenocarcinoma, FBXO32 methylation and Myc stabilization in diabetic retinopathy, and USP7-DNMT1 complexes in renal fibrosis and HCC recurrence. NTX-301 and sotagliflozin extend this work toward pharmacologic epigenetic modulation, including Hippo and HDAC pathways. The settings remain too diverse to define one unified therapeutic direction.

    6 papers · 66.7%

  • Computational DNMT1 Inhibitor Discovery

    Computational screening is being used to prioritize phytochemicals as potential DNMT1 inhibitors for breast cancer. Molecular docking, density functional theory and molecular dynamics assess binding, stability and drug-like interactions. 1,2,3,4,6-O-pentagalloylglucose and related PlantCyc compounds emerge as candidate scaffolds. Experimental validation of DNMT1 inhibition and anticancer activity remains the key unresolved step.

    2 papers · 22.2%

  • Epigenetic Therapy in Prostate Cancer

    Combined BET bromodomain and DNMT1 inhibition is moving toward treatment of transdifferentiated prostate cancer. The approach targets survival programs shaped by TP53, RB transcriptional corepressor 1, chromatin accessibility and DNA methylation. Dual blockade appears more promising than either epigenetic intervention alone. The open question is whether these molecular effects translate into durable tumour control.

    1 papers · 11.1%

Papers

The 9 papers from the last 6 months that study DNMT1 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

DNMT1 Disease Mechanisms (6)
  1. DNMT1 is associated with QDPR downregulation and chemotherapy response in lung adenocarcinoma. Medical oncology (Northwood, London, England) · 1 Sept 2026 PMID 42678580
  2. Sotagliflozin, a Dual SGLT1/2 Inhibitor, Modulates DNMT1 and Class I/II HDAC Expression in Association With Anticancer Effects in Breast and Lung Cancer Cells. Cell biology international · 1 Sept 2026 PMID 42677956
  3. The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42439804
  4. HSP90α-USP7-DNMT1 axis drives HCC recurrence after microwave ablation by disrupting ACSS3-mediated propionate metabolism. Molecular therapy : the journal of the American Society of Gene Therapy · 27 Jun 2026 PMID 42363602
  5. DNMT1 methylates E3 ligase FBXO32 to regulate Myc stability and glycolytic reprogramming in diabetic retinopathy associated endothelial cells. Journal of bioenergetics and biomembranes · 25 Jun 2026 PMID 42348038
  6. Pirfenidone Elevates GLIS1 by Disrupting the USP7/DNMT1 Complex and Alleviates Renal Fibrosis in Diabetic Kidney Disease Through ROS Reduction and TGF-β1/Smad Signaling Inhibition. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 20 May 2026 PMID 42159303
Computational DNMT1 Inhibitor Discovery (2)
  1. Phytochemical modulation of DNMT1-mediated DNA methylation: computational insights into breast cancer. Journal of molecular modeling · 18 Oct 2026 PMID 42891767
  2. In silico identification of DNMT1 inhibitors from the PlantCyc database through computational approach to assess the anti-cancer potential of nutraceutical compounds in breast cancer. Journal of molecular graphics & modelling · 21 Jun 2026 PMID 42323936
Epigenetic Therapy in Prostate Cancer (1)
  1. Combined BET bromodomain and DNA methyltransferase inhibition targets critical survival pathways in transdifferentiated prostate cancer. JCI insight · 11 Aug 2026 PMID 42579341

By study type

Human data, design not indexed (3)
  1. Phytochemical modulation of DNMT1-mediated DNA methylation: computational insights into breast cancer. Journal of molecular modeling · 18 Oct 2026 PMID 42891767
  2. DNMT1 methylates E3 ligase FBXO32 to regulate Myc stability and glycolytic reprogramming in diabetic retinopathy associated endothelial cells. Journal of bioenergetics and biomembranes · 25 Jun 2026 PMID 42348038
  3. In silico identification of DNMT1 inhibitors from the PlantCyc database through computational approach to assess the anti-cancer potential of nutraceutical compounds in breast cancer. Journal of molecular graphics & modelling · 21 Jun 2026 PMID 42323936
Preclinical: animal, cell and lab studies (6)
  1. DNMT1 is associated with QDPR downregulation and chemotherapy response in lung adenocarcinoma. Medical oncology (Northwood, London, England) · 1 Sept 2026 PMID 42678580
  2. Sotagliflozin, a Dual SGLT1/2 Inhibitor, Modulates DNMT1 and Class I/II HDAC Expression in Association With Anticancer Effects in Breast and Lung Cancer Cells. Cell biology international · 1 Sept 2026 PMID 42677956
  3. Combined BET bromodomain and DNA methyltransferase inhibition targets critical survival pathways in transdifferentiated prostate cancer. JCI insight · 11 Aug 2026 PMID 42579341
  4. The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42439804
  5. HSP90α-USP7-DNMT1 axis drives HCC recurrence after microwave ablation by disrupting ACSS3-mediated propionate metabolism. Molecular therapy : the journal of the American Society of Gene Therapy · 27 Jun 2026 PMID 42363602
  6. Pirfenidone Elevates GLIS1 by Disrupting the USP7/DNMT1 Complex and Alleviates Renal Fibrosis in Diabetic Kidney Disease Through ROS Reduction and TGF-β1/Smad Signaling Inhibition. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 20 May 2026 PMID 42159303